<DOC>
	<DOCNO>NCT01007175</DOCNO>
	<brief_summary>This primary purpose study evaluate safety , tolerability , pharmacokinetic property multiple ascend dos ATN-103 administer subcutaneously ( skin ) Japanese subject active rheumatoid arthritis stable background methotrexate . Some subject receive ATN-103 subject receive placebo .</brief_summary>
	<brief_title>Study Evaluating Multiple Ascending Doses Of ATN-103 In Japanese Subjects With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Meets ACR 1987 revise criterion classification Rheumatoid Arthritis ( RA ) . ACR functional class I III . Active RA time screen baseline consist = 6 swell = 6 tender joint least . hsCRP level = 8 mg/L . Must receive MTX least 12 wks , stable dose route MTX least 6 wks prior baseline continue dose duration study . The report chest xray perform within 12 wks screen document absence evidence malignancy , infection , abnormality suggestive TB must obtain available subject 's study file prior baseline . All WOCBP must negative pregnancy test result screen baseline . All WOCBP sexual intercourse nonsurgically sterilize male partner must agree commit use follow highly effective form contraception duration study 8 wks last dose investigational product . All male subject biologically capable father child must agree commit use reliable method birth control duration study 8 wks last dose investigational product . Pregnant breastfeed woman . Presence active infection open cutaneous ulcer underlie disease could predispose subject infection history serious infection within 4 wks baseline . A history current evidence latent active TB , evidence prior currently active TB chest Xray , recent close contact individual active TB , positive Mantoux tuberculin skin test . Other significant concurrent medical condition time screen baseline . Laboratory abnormalities screen . Positive HBsAg , HBcAb , and/or HepCAb . ALTand/or AST= 2 time ULN high . Hemoglobin = 8.5 g/dL low . Platelet = 125,000 /mm³ low , = 1,000,000 /mm³ high . WBC = 3500 /mm³ low . Serum creatinine= 2 mg/dL high . Any prior use B celldepleting therapy . Receipt within 24 wks baseline visit : Any cytotoxic drug . Leflunomide . Any investigational biological drug ( ) . Receipt within 12 wks baseline visit : Any biological drug list exclusion criterion . Any surgical joint intervention ( open arthroscopic ) . Any investigational drug ( investigational biological drug ) , procedure , device . Receipt within 8 wks baseline : Abatacept . Any type TNF inhibitor list exclusion criterion . Receipt within 4 wks baseline : Any DMARDs , stable background MTX , immunosuppressive drug list exclusion criterion . Etanercept . IA hyaluronic acid injection . Any live ( attenuate ) vaccine . Receipt within 2 wks baseline : &gt; 10 mg/day oral prednisone equivalent , change dose oral prednisone equivalent . IA , bolus IM , IV treatment corticosteroid . &gt; 1 NSAID , change dose NSAID , NSAID use great maximum recommend dose . Initiation statins dosage adjustment current statin . Change dose folic acid . Known suspected allergy ATN103 , type TNF inhibitor , human immunoglobulin protein , compound related class medication . Current history psychiatric disease alcohol drug abuse , opinion investigator , would interfere ability comply study protocol give informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>TNF inhibitor</keyword>
	<keyword>Multiple ascend dose study</keyword>
</DOC>